MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-022-01713-y

Медицинская библиотека · Leukemia · 2022

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.

Seifert Robert, Kersting David, Rischpler Christoph, Sandach Patrick, Ferdinandus Justin, Fendler Wolfgang P, Rahbar Kambiz, Weckesser Matthias, Umutlu Lale, Hanoun Christine, Hüttmann Andreas, Reinhardt Hans Christian, von Tresckow Bastian, Herrmann Ken, Dührsen Ulrich, Schäfers Michael

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUVAI) and the mean FDG uptake of all lymphoma manifestations (mean-SUVAI). High mean-SUVAI uptake was determined separately for iPET-positive and iPET-negative patients. The endpoint was time-to-progression (TTP). There was a significant interaction of additional rituximab and mean-SUVAI in the iPET-negative group (HR = 0.6, p < 0.05). Patients with high mean-SUVAI had significantly prolonged TTP when treated with 6xR-CHOP + 2 R (not reached versus 52 months, p < 0.05), whereas max-SUVmanual failed to show an impact of additional rituximab. In the iPET-positive group, patients with high mean-SUVAI had a significantly longer TTP with (R-)CHOP than with the Burkitt protocol (14 versus 4 months, p < 0.01). Comprehensive iPET evaluation may provide new prognosticators in aggressive lymphoma. Additional application of rituximab was associated with prolonged TTP in iPET-negative patients with high mean-SUVAI. Comprehensive iPET interpretation could identify high-risk patients who benefit from study-specific interventions.

Для цитирования: Seifert Robert, Kersting David, Rischpler Christoph, Sandach Patrick, Ferdinandus Justin, Fendler Wolfgang P, Rahbar Kambiz, Weckesser Matthias, Umutlu Lale, Hanoun Christine, Hüttmann Andreas, Reinhardt Hans Christian, von Tresckow Bastian, Herrmann Ken, Dührsen Ulrich, Schäfers Michael. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.. Leukemia. 2022. DOI: 10.1038/s41375-022-01713-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.